Virosomes of hepatitis B virus envelope L proteins containing doxorubicin: Synergistic enhancement of human liver-specific antitumor growth activity by radiotherapy

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 4159-4172

  Liu, Qiushi ^a,b   Jung, Joohee ^c,d   Somiya, Masaharu ^a,b,e   Iijima, Masumi ^a,b   Yoshimoto, Nobuo ^a,b   Niimi, Tomoaki ^a   Maturana, Andrés D ^a   Shin, Seol Hwa ^c   Jeong, Seong Yun ^c   Choi, Eun Kyung ^c   Kuroda, Shun’ichi ^a,b  

^a NAGOYA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c University of Ulsan College of Medicine   (South Korea)

^d Duksung Women's University   (South Korea)

^e JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

Author keywords

Bionanocapsule; Chemoradiotherapy; Doxorubicin; Drug delivery system; Liposomes; Targeting

Indexed keywords

DIHYDROLIPOAMIDE DEHYDROGENASE; DOXORUBICIN; LIPOSOME; VIROSOME; ANTINEOPLASTIC AGENT; L PROTEIN, HEPATITIS B VIRUS; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; CELLULAR DISTRIBUTION; CHEMORADIOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG MEGADOSE; ENCAPSULATION; HEPATITIS B VIRUS; HIGH TEMPERATURE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER CELL CARCINOMA; LOW DRUG DOSE; MALE; MAMMAL CELL; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PROCESS OPTIMIZATION; TUMOR GROWTH; TUMOR VOLUME; WEIGHT REDUCTION; ANIMAL; CHEMISTRY; DRUG SCREENING; LIVER; LIVER TUMOR; METABOLISM; PROCEDURES; RADIOTHERAPY; TUMOR CELL LINE;

HEPATITIS B VIRUS; MAMMALIA; MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOXORUBICIN; HUMANS; LIVER; LIVER NEOPLASMS; MICE; RADIOTHERAPY; VIRAL ENVELOPE PROTEINS; VIROSOMES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84933574483     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S84295     Document Type: Article

References (33)

1. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotech-nology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2014;66:2–25.
2. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65(1–2):274–281.
3. Goren D, Horowitz AT, Tzemach D, et al. Nuclear delivery of doxoru-bicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res. 2000;6(5):1949–1957.
4. Iinuma H, Maruyama K, Okinaga K, et al. Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int J Cancer. 2002;99(1): 130–137.
5. Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release. 2012; 161(2):175–187.
6. Kunjachan S, Pola R, Gremse F, et al. Passive versus active tumor targeting using RGD- and NGR-modified polymeric nanomedicines. Nano Lett. 2014;14(2):972–981.
7. Torchilin VP. Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol. 2010;197:3–53.
8. Heerman KH, Goldman U, Schwartz W, et al. Large surface proteins of hepatitis B virus containing the pre-s sequence. J Virol. 1984;52(2): 396–402.
9. Bruss V, Ganem D. The role of envelope proteins in hepatitis B virus assembly. Proc Natl Acad Sci U S A. 1991;88(3):1059–1063.
10. Le Seyec J, Chouteau P, Cannie I, Guguen-Guillouzo C, Gripon P. Infection process of the hepatitis B virus depends on the presence of a defined sequence in the pre-S1 domain. J Virol. 1999;73(3):2052–2057.
11. Neurath AR, Kent SB, Strick N, Parker K. Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell. 1986; 46(3):429–436.
12. Kuroda S, Otaka S, Miyazaki T, Nakao M, Fujisawa Y. Hepatitis B virus envelope L protein particles: synthesis and assembly in Saccharomyces cerevisiae, purification, and characterization. J Biol Chem. 1992;267(3): 1953–1961.
13. Jung J, Iijima M, Yoshimoto N, et al. Efficient and rapid purification of drug- and gene-carrying bio-nanocapsules, hepatitis B virus surface antigen L particles, from Saccharomyces cerevisiae. Protein Expr Purif. 2011; 78(2):149–155.
14. Yamada T, Iwabuki H, Kanno T, et al. Physicochemical and immunolog-ical characterization of hepatitis B virus envelope particles exclusively consisting of the entire L (pre-S1 + pre-S2 + S) protein. Vaccine. 2001; 19(23–24):3154–3163.
15. Yamada M, Oeda A, Jung J, et al. Hepatitis B virus envelope L protein-derived bio-nanocapsules: mechanisms of cellular attachment and entry into human hepatic cells. J Control Release. 2012;160(2):322–329.
16. Yamada T, Iwasaki Y, Tada H, et al. Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nat Biotechnol. 2003;21(8): 885–890.
17. Jung J, Matsuzaki T, Tatematsu K, et al. Bio-nanocapsule conjugated with liposomes for in vivo pinpoint delivery of various materials. J Control Release. 2008;126(3):255–264.
18. Kasuya T, Jung J, Kinoshita R, et al. Bio-nanocapsule-liposome conjugates for in vivo pinpoint drug and gene delivery. Methods Enzymol. 2009;464:147–166.
19. Kaneda Y. Virosomes: evolution of the liposome as a targeted drug delivery system. Adv Drug Deliv Rev. 2000;43(2–3):197–205.
20. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20(4):470–475.
21. Lasic DD, Čeh B, Stuart MC, et al. Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery. Biochim Biophys Acta. 1995;1239(2):145–156.
22. Haran G, Cohen R, Bar LK, Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta. 1993;1151(2): 201–215.
23. Oess S, Hildt E. Novel cell permeable motif derived from the PreS2-domain of hepatitis-B virus surface antigens. Gene Ther. 2000;7(9): 750–758.
24. Rodrıguez-Crespo I, Núñez E, Yélamos B, et al. Fusogenic activity of hepadnavirus peptides corresponding to sequences downstream of the putative cleavage site. Virology. 1999;261(1):133–142.
25. Kobayashi M, Asano T, Utsunomiya M, et al. Recombinant hepatitis B virus surface antigen carrying the pre-S2 region derived from yeast: purification and characterization. J Biotechnol. 1988;8(1):1–21.
26. Barenholz Y. Doxil® – the frst FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117–134.
27. Wang J, Byrne JD, Napier ME, DeSimone JM. More effective nano-medicines through particle design. Small. 2011;7(14):1919–1931.
28. Xiao K, Li Y, Luo J, et al. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials. 2011;32(13):3435–3446.
29. Watashi K, Urban S, Li W, Wakita T. NTCP and beyond: opening the door to unveil hepatitis B virus entry. Int J Mol Sci. 2014;15(2): 2892–2905.
30. Raz R, Koren R, Bass D. Safety and immunogenicity of a new mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens in adults. Isr Med Assoc J. 2001;3:328–332.
31. Shouval D, Roggendorf H, Roggendorf M. Enhanced immune response to hepatitis B vaccination through immunization with a pre-S1/pre-S2/S vaccine. Med Microbiol Immunol. 2015;204:57–68.
32. Lammers T, Hennink WE, Storm G. Tumor-targeted nanomedicines: principles and practice. Br J Cancer. 2008;99(3):392–397.
33. Lammers T, Subr V, Peschke P, et al. Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy. Br J Cancer. 2008;99(6):900–910.